Latest news with #CogentBiosciences
Malaysian Reserve
31-07-2025
- Business
- Malaysian Reserve
KIT Inhibitors Market Growth: Key Trends and Future Projections in the 7MM Upto 2034
The KIT inhibitors market remains highly competitive, driven by established players such as ONO Pharmaceutical and Blueprint Medicines, among others. At the same time, companies like Celldex Therapeutics, Cogent Biosciences, and Blueprint Medicines¸, among others, are actively advancing pipeline candidates across various stages of development. This sustained R&D activity reflects ongoing innovation and intensifying competition within the KIT-targeted therapy landscape. LAS VEGAS, July 31, 2025 /PRNewswire/ — DelveInsight's KIT Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Systemic Mastocytosis, Gastrointestinal Stromal Tumor (GIST), Chronic Spontaneous Urticaria (CSU), Graft-versus-host Disease (GvHD), Tenosynovial Giant Cell Tumor (TGCT), Advanced Systemic Mastocytosis (AdvSM), Non-advanced Systemic Mastocytosis (NonAdvSM), Indolent Systemic Mastocytosis (ISM), and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging KIT inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the KIT Inhibitors Market Report As per DelveInsight's analysis, the total market size of KIT inhibitors in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such as Systemic Mastocytosis, Gastrointestinal Stromal Tumor (GIST), Chronic Spontaneous Urticaria (CSU), Graft-versus-host Disease (GvHD), Tenosynovial Giant Cell Tumor (TGCT), Advanced Systemic Mastocytosis (AdvSM), Non-advanced Systemic Mastocytosis (NonAdvSM), Indolent Systemic Mastocytosis (ISM), and others. Leading KIT inhibitors companies, such as Celldex Therapeutics, Cogent Biosciences, Blueprint Medicines, and others, are developing novel KIT inhibitors that can be available in the KIT inhibitors market in the coming years. Some of the key KIT inhibitors in the pipeline include Barzolvolimab (CDX-0159), Bezuclastinib (CGT9486), Elenestinib (BLU-263), and others. Discover which indication is expected to grab the major KIT inhibitors market share @ KIT Inhibitors Market Report KIT Inhibitors Market Dynamics The KIT inhibitors market is shaped by a combination of growing clinical demand, limited therapeutic options, and ongoing advancements in targeted therapies. KIT, a receptor tyrosine kinase, plays a crucial role in cell growth and survival, and its mutations are strongly linked to malignancies such as gastrointestinal stromal tumors (GIST), systemic mastocytosis, and certain leukemias. The rising incidence of these cancers and the need for more effective treatments have fueled the demand for KIT inhibitors. However, the current landscape is dominated by a few branded drugs, such as AYVAKIT (avapritinib), QINLOCK (ripretinib), and ROMVIMZA (vimseltinib), with no generic options available, reflecting a relatively narrow competitive field. A key market driver is the increasing understanding of KIT-driven oncogenesis and the development of highly selective inhibitors that can overcome resistance to first-generation therapies. For example, mutations in the KIT gene often lead to resistance against older drugs like imatinib, pushing the need for next-generation inhibitors with improved efficacy and tolerability. In addition, strategic collaborations, licensing agreements, and FDA fast-track designations for KIT-targeting agents have accelerated innovation, further supporting market growth. Biopharmaceutical companies are also investing heavily in research to explore KIT inhibition beyond GIST, expanding the potential market size. Despite these opportunities, the KIT inhibitors market faces notable challenges. The high cost of branded therapies and strict reimbursement policies in several regions can limit patient access, especially in emerging economies. Moreover, the complexity of targeting KIT mutations, which often co-occur with other genetic alterations, makes drug development challenging and leads to high attrition rates in clinical trials. Competition from alternative treatment modalities, including immunotherapies and other targeted agents, also poses a threat to the growth of this niche segment. Looking ahead, the KIT inhibitors market is expected to witness steady growth as novel agents enter the pipeline and existing drugs gain approvals for expanded indications. Personalized medicine approaches, including genetic testing and biomarker-driven therapy selection, will play a critical role in shaping treatment protocols. Advances in drug design, such as allosteric inhibitors and combination regimens targeting resistance pathways, are likely to create new opportunities, making this a dynamic and evolving therapeutic area over the next decade. KIT Inhibitors Treatment Market The current landscape of US FDA-approved KIT inhibitors is relatively narrow, with only a few branded therapies available, such as ROMVIMZA (vimseltinib), AYVAKIT (avapritinib), and QINLOCK (ripretinib), and no generic alternatives on the market. This limited competition highlights the inherent challenges of effectively targeting KIT mutations. ROMVIMZA is an oral kinase inhibitor with high selectivity for the colony-stimulating factor 1 receptor (CSF1R). Preclinical research has shown that vimseltinib inhibits CSF1R autophosphorylation, blocks ligand-stimulated signaling, and reduces the proliferation of CSF1R-positive cells. It is indicated for adults with symptomatic TGCT where surgical resection would likely result in major functional impairment or severe complications. In February 2025, the US FDA approved ROMVIMZA for this indication. Previously, in July 2024, the EMA accepted the marketing authorization application (MAA) for vimseltinib in TGCT. The drug is also being evaluated in a Phase II trial for chronic GvHD. QINLOCK is a broad-spectrum tyrosine kinase inhibitor designed to target KIT and PDGFRA, including both wild-type and resistant primary and secondary mutations frequently seen in GIST. It also demonstrates in vitro activity against kinases such as PDGFRB, TIE2, VEGFR2, and BRAF. Clinically, QINLOCK is approved for adults with advanced GIST who have progressed after at least three prior kinase inhibitors, including imatinib, filling a critical therapeutic gap in later-line treatment. QINLOCK received FDA approval in May 2020, followed by European Commission approval in November 2021. AYVAKIT is a potent and selective tyrosine kinase inhibitor that targets key activating mutations in KIT and PDGFRA, including KIT D816V and PDGFRA D842V, with sub-nanomolar to low nanomolar activity in preclinical studies. It effectively inhibits autophosphorylation and cell proliferation in KIT-driven and PDGFRA-resistant models. Clinically, AYVAKIT is approved for unresectable or metastatic GIST with PDGFRA exon 18 mutations (including D842V), as well as AdvSM and ISM, but its use is restricted in patients with platelet counts below 50×10⁹/L. It was first approved by the FDA in January 2020 for adults with unresectable or metastatic GIST harboring PDGFRA exon 18 mutations, including D842V—the first therapy to specifically target this mutation. The European Commission subsequently granted conditional marketing authorization under the name AYVAKYT in September 2020 for monotherapy in adults with unresectable or metastatic GIST carrying PDGFRA D842V mutations. Learn more about the KIT inhibitors @ KIT Inhibitors Analysis Key Emerging KIT Inhibitors and Companies A growing pipeline of KIT inhibitors is being investigated across a diverse set of indications beyond oncology, including CSU, multiple sclerosis, and GvHD. Prominent candidates such as barzolvolimab (CDX-0159), bezuclastinib (CGT9486), and elenestinib (BLU-263), among others, reflect this expanding therapeutic interest, signaling the potential of KIT-targeted therapies in addressing immune-mediated and inflammatory conditions. Barzolvolimab is a humanized monoclonal antibody that specifically targets the receptor tyrosine kinase KIT, effectively blocking its activity. By inhibiting KIT signaling, which regulates mast cell development, survival, and function, barzolvolimab tackles a critical driver of mast cell–mediated inflammatory processes. This mechanism is especially significant in diseases like chronic urticaria, where abnormal mast cell activation is central to disease progression. Barzolvolimab is in various stages of clinical development for multiple inflammatory disorders, including chronic spontaneous urticaria, chronic inducible urticaria, eosinophilic esophagitis, prurigo nodularis, and atopic dermatitis, with CSU being the most advanced program, currently in Phase III. At the EAACI Congress in June 2025, Celldex Therapeutics presented strong Phase II data showing durable complete responses and notable quality-of-life improvements at 76 weeks, extending well beyond the dosing period. Additional data revealed significant reductions in angioedema at 52 weeks, reinforcing barzolvolimab's potential as a transformative therapy for CSU. Bezuclastinib (CGT9486) is a highly selective and potent tyrosine kinase inhibitor (TKI) that targets the KIT D816V mutation, a primary driver in most systemic mastocytosis cases, as well as other KIT exon 17 mutations often found in advanced gastrointestinal stromal tumors. It is being developed for patients with non-advanced systemic mastocytosis (NonAdvSM), advanced systemic mastocytosis (AdvSM), and GIST. In February 2025, Cogent Biosciences presented data on the efficacy and safety of bezuclastinib in adult patients with NonAdvSM from the Phase II SUMMIT trial at the AAAAI Annual Meeting (February 28–March 3, 2025). Cogent Biosciences aims to achieve key milestones for bezuclastinib in 2025: release top-line Phase II SUMMIT trial data for NonAdvSM in July; report Phase II APEX trial results in AdvSM in the second half of the year; submit the first New Drug Application (NDA) by year-end; and present top-line results from the pivotal Phase III PEAK trial in imatinib-resistant GIST patients by late 2025. Elenestinib (BLU-263) is an investigational oral, potent, and highly selective inhibitor of KIT D816V, designed for the treatment of indolent systemic mastocytosis (ISM) and other mast cell disorders. It is engineered to offer similar potency to avapritinib while minimizing off-target effects and central nervous system penetration. Elenestinib is currently being studied in the ongoing registration-enabling Phase II/III HARBOR trial in ISM, which includes a dose-finding Part 1, a registration-focused Part 2, and a long-term treatment Part 3. Top-line 12-week results from Part 1 of the HARBOR trial were announced in December 2022 and subsequently presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2023. The anticipated launch of these emerging therapies is poised to transform the KIT inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the KIT inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about KIT inhibitors clinical trials, visit @ KIT Inhibitors Treatment KIT Inhibitors Overview KIT inhibitors are a class of targeted therapies designed to block the activity of the KIT receptor tyrosine kinase, which plays a crucial role in cell proliferation, survival, and differentiation. Mutations or overactivation of KIT are implicated in several malignancies, including gastrointestinal stromal tumors and mastocytosis. By inhibiting KIT signaling, these drugs disrupt oncogenic pathways and help control tumor growth or abnormal cell proliferation. The therapeutic development of KIT inhibitors continues to evolve, with newer agents being designed to overcome resistance mechanisms associated with first-generation TKIs. Resistance often arises due to secondary mutations in the KIT gene, leading to reduced drug binding and diminished efficacy. Advanced KIT inhibitors have been developed to address these resistance mutations by offering broader and more potent inhibition across multiple KIT variants. Ongoing research is focused on combination therapies, improved selectivity, and minimizing adverse effects, aiming to expand the clinical utility of KIT inhibitors across a wider range of cancers and other KIT-mediated disorders. KIT Inhibitors Epidemiology Segmentation The KIT inhibitors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases in Selected Indications for KIT Inhibitor Total Eligible Patient Pool in Selected Indications for KIT Inhibitor Total Treated Cases in Selected Indications for KIT Inhibitor KIT Inhibitors Report Metrics Details Study Period 2020–2034 KIT Inhibitors Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report Systemic Mastocytosis, Gastrointestinal Stromal Tumor (GIST), Chronic Spontaneous Urticaria (CSU), Graft-versus-host Disease (GvHD), Tenosynovial Giant Cell Tumor (TGCT), Advanced Systemic Mastocytosis (AdvSM), Non-advanced Systemic Mastocytosis (NonAdvSM), Indolent Systemic Mastocytosis (ISM), and others Key KIT Inhibitors Companies Celldex Therapeutics, Cogent Biosciences, Blueprint Medicines, ONO Pharmaceutical (Deciphera Pharmaceuticals), Blueprint Medicines, and others Key KIT Inhibitors Barzolvolimab (CDX-0159), Bezuclastinib (CGT9486), Elenestinib (BLU-263), ROMVIMZA (vimseltinib), QINLOCK (ripretinib), AYVAKIT/AYVAKYT (avapritinib), and others Scope of the KIT Inhibitors Market Report KIT Inhibitors Therapeutic Assessment: KIT Inhibitors current marketed and emerging therapies KIT Inhibitors Market Dynamics: Conjoint Analysis of Emerging KIT Inhibitors Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, KIT Inhibitors Market Access and Reimbursement Discover more about KIT inhibitors in development @ KIT Inhibitors Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary 4 Key Events 5 Market Forecast Methodology 6 KIT Inhibitor Market Overview at a Glance in the 7MM 6.1 Market Share (%) Distribution by Indication in 2024 6.2 Market Share (%) Distribution by Indication in 2034 7 KIT Inhibitor: Background and Overview 7.1 Introduction 7.2 Evolution of KIT Inhibitor 7.3 Treatment 8 Target Patient Pool 8.1 Key Findings 8.2 Assumptions and Rationale: 7MM 8.3 Epidemiology Scenario in the 7MM 8.3.1 Total Cases in Selected Indications for KIT Inhibitor in the 7MM 8.3.2 Total Eligible Patient Pool in Selected Indications for KIT Inhibitor in the 7MM 8.3.3 Total Treated Cases in Selected Indications for KIT Inhibitor in the 7MM 8.4 The US 8.5 EU4 and the UK 8.6 Japan 9 Marketed Therapies 9.1 Key Cross Competition 9.2 ROMVIMZA (vimseltinib): ONO Pharmaceutical (Deciphera Pharmaceuticals) 9.2.1 Product Description 9.2.2 Regulatory Milestones 9.2.3 Others Developmental Activities 9.2.4 Clinical Trials Information 9.2.5 Safety and Efficacy 9.3 QINLOCK (ripretinib): ONO Pharmaceutical (Deciphera Pharmaceuticals) 9.4 AYVAKIT/AYVAKYT (avapritinib): Blueprint Medicines List of drugs to be continued in the final report… 10 Emerging Therapies 10.1 Key Cross Competition 10.2 Barzolvolimab (CDX-0159): Celldex Therapeutics 10.2.1 Drug Description 10.2.2 Others Developmental Activities 10.2.3 Clinical Trials Information 10.2.4 Safety and Efficacy 10.2.5 Analyst's View 10.3 Bezuclastinib (CGT9486): Cogent Biosciences 10.4 Elenestinib (BLU-263): Blueprint Medicines List of drugs to be continued in the final report… 11 KIT Inhibitor: the 7MM Analysis 11.1 Key Findings 11.2 Key Market Forecast Assumptions 11.2.1 Cost Assumptions and Rebates 11.2.2 Pricing Trends 11.2.3 Analogue Assessment 11.2.4 Launch Year and Therapy Uptakes 11.3 Market Outlook 11.4 Attribute Analysis 11.5 Total Market Size of KIT Inhibitor in the 7MM 11.6 The US Market Size 11.6.1 Total Market Size of KIT Inhibitor in the US 11.6.2 Market Size of KIT Inhibitor by Therapies in the US 11.7 EU4 and the UK Market Size 11.7.1 Total Market Size of KIT Inhibitor in EU4 and the UK 11.7.2 Market Size of KIT Inhibitor by Therapies in EU4 and the UK 11.8 Japan Market Size 11.8.1 Total Market Size of KIT Inhibitor in Japan 11.8.2 Market Size of KIT Inhibitor by Therapies in Japan 12 Unmet Needs 13 SWOT Analysis 14 KOL Views 15 Market Access and Reimbursement 15.1 The US 15.2 EU4 and the UK 15.3 Japan 16 Acronyms and Abbreviations 17 Bibliography Related Reports Gastrointestinal Stromal Tumor Market Gastrointestinal Stromal Tumor Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GIST companies, including Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, Ascentage Pharma, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor Inc., DNAtrix Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx Inc., Allarity Therapeutics, among others. Chronic Spontaneous Urticaria Market Chronic Spontaneous Urticaria Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CSU companies, including Celldex Therapeutics, Novartis, Sanofi, Incyte, Jasper Therapeutics, InflaRx, Evommune, Otsuka Holdings (Taiho Pharmaceutical), among others. Graft Versus Host Disease Market Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GvHD companies, including CSL Behring, Equillium, Biocon, MaaT Pharma, REGiMMUNE, ReAlta Life Sciences, Ono Pharmaceutical (Deciphera Pharmaceuticals), Medsenic, BioSenic, ASC Therapeutics, Cynata Therapeutics, Evive Biotech (Yifan Pharmaceutical), Ironwood, medac, among others. Systemic Mastocytosis Market Systemic Mastocytosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key systemic mastocytosis companies, including AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content:
Yahoo
26-07-2025
- Business
- Yahoo
Cogent Biosciences Rated as a Buy at Citi on Robust Pipeline
Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 18, Citi raised its price target of the stock to $22 from $15 while maintaining a 'Buy' rating. A doctor reading the results of a Phase 2 clinical trial of treatments for cancer, infectious diseases and autoimmune and inflammatory diseases. The price target hike comes as the company delivers top-line results from bezuclastinib (bezu) in non-advanced systemic mastocytosis (NonAdvSM). According to Citi, investors are increasingly viewing bezuclastinib as an improvement over Blueprint's Ayvakit. The research firm expects the company to deliver positive symptom and biomarker data at ASH in December. Beyond bezuclastinib, Cogent Biosciences is also advancing its other pipeline candidates. The company plans to release advanced systemic mastocytosis (AdvSM) data from the APEX trial in the second half of the year. It will also provide results from the PEAK trial for gastrointestinal stromal tumors (GIST). Cogent Biosciences, Inc. (NASDAQ:COGT) is a biotechnology company that develops precision therapies for genetically defined diseases. It focuses on diseases caused by genetic mutations. Its lead program, bezuclastinib, is a tyrosine kinase inhibitor designed to target the KIT D816V mutation, which drives systemic mastocytosis, as well as other mutations in KIT exon 17. While we acknowledge the potential of COGT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-07-2025
- Business
- Yahoo
Jefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating
Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the 10 Best Small-Cap Stocks to Buy According to Billionaires. On July 7, Jefferies increased its price target on Cogent Biosciences, Inc. (NASDAQ:COGT) from $23 to $28 and reiterated a 'Buy' rating. This decision came as the research firm noted strong results from the SUMMIT trial for non-advanced systemic mastocytosis (non-AdvSM). All of the trial's primary and secondary endpoints achieved statistically significant comparisons in favor of bezuclastinib over placebo. A group of scientists in a laboratory researching a sophisticated biotechnology drug. The data showed a reduction of -8.91 in placebo-adjusted Total Symptom Score (TSS). Jefferies analysts pointed out that this is about 57% better than the competing drug Ayvakit. These results are even more impressive because Cogent Biosciences, Inc.'s (NASDAQ:COGT) trial included patients with more severe baseline conditions. According to the research note, the safety results were also positive, as Grade 3 AST/ALT elevations came in at 5.9%. This is an improvement from the 10% seen in earlier data. Jefferies analysts believe that Cogent Biosciences, Inc. (NASDAQ:COGT) will have a market opportunity of approximately $1 billion for bezuclastinib in indolent systemic mastocytosis (ISM). The drug has additional potential in advanced systemic mastocytosis (ASM) and gastrointestinal stromal tumor (GIST), which means the total addressable market could grow. Cogent Biosciences, Inc. (NASDAQ:COGT) is a biotechnology company focused on developing precision therapies for genetically defined diseases. While we acknowledge the potential of COGT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Business Insider
12-07-2025
- Business
- Business Insider
Analysts Are Bullish on Top Healthcare Stocks: Neurogene (NGNE), Cogent Biosciences (COGT)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurogene (NGNE – Research Report) and Cogent Biosciences (COGT – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Neurogene (NGNE) Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Neurogene on July 7 and set a price target of $46.00. The company's shares closed last Friday at $21.43, close to its 52-week low of $13.47. According to Matteis is a 3-star analyst with an average return of 2.8% and a 43.2% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Sionna Therapeutics, Inc., KalVista Pharmaceuticals, and BioMarin Pharmaceutical. Currently, the analyst consensus on Neurogene is a Strong Buy with an average price target of $38.20, implying a 76.5% upside from current levels. In a report issued on June 30, BMO Capital also maintained a Buy rating on the stock with a $26.00 price target. Cogent Biosciences (COGT) In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Cogent Biosciences, with a price target of $20.00. The company's shares closed last Friday at $10.98. According to Slutsky has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -2.6% and a 38.8% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Abivax SA Sponsored ADR, and Olema Pharmaceuticals. Cogent Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $18.64, a 74.7% upside from current levels. In a report issued on June 30, Citi also maintained a Buy rating on the stock with a $15.00 price target.
Globe and Mail
16-06-2025
- Business
- Globe and Mail
Systemic Mastocytosis Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 8+ Companies and 8+ Therapies
DelveInsight's, 'Systemic Mastocytosis Pipeline Insight, 2025,' report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Systemic Mastocytosis pipeline landscape. It covers the Systemic Mastocytosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Systemic Mastocytosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Systemic Mastocytosis Pipeline. Dive into DelveInsight's comprehensive report today! @ Systemic Mastocytosis Pipeline Outlook Key Takeaways from the Systemic Mastocytosis Pipeline Report In May 2025, M.D. Anderson Cancer Center announced a clinical research study is to see if RAD001 can help to control the disease in patients with systemic mastocytosis (SM). The safety of this treatment will also be studied. RAD001 is designed to stop cancer cells from multiplying. It may also stop the growth of new blood vessels that help tumor growth, which may cause the tumor cells to die. In May 2025, Cogent Biosciences Inc. announced a Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL). DelveInsight's Systemic Mastocytosis Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Systemic Mastocytosis treatment. The leading Systemic Mastocytosis Companies such as AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology and others. Promising Systemic Mastocytosis Pipeline Therapies such as PA101, Avapritinib, RAD001 (Everolimus), Elenestinib, Masitinib, Avapritinib, Brentuximab vedotin, TL-895 and others. Stay ahead with the most recent pipeline outlook for Systemic Mastocytosis. Get insights into clinical trials, emerging therapies, and leading companies with Systemic Mastocytosis @ Systemic Mastocytosis Treatment Drugs Systemic Mastocytosis Emerging Drugs Profile Avapritinib: Blueprint Medicines Avapritinib is a potent and selective inhibitor of activated KIT and PDGFRA mutant kinases. In certain diseases, mutations in KIT and PDGFRA force protein kinases into an increasingly active state. Avapritinib is uniquely designed to bind and inhibit the active conformation of these proteins. Blueprint Medicines is developing AYVAKIT globally for the treatment of advanced and indolent SM. Blueprint Medicines has an exclusive collaboration and license agreement with CStone Pharmaceuticals for the development and commercialization of AYVAKIT in Mainland China, Hong Kong, Macau and Taiwan. Blueprint Medicines retains development and commercial rights for AYVAKIT in the rest of the world. The FDA granted breakthrough therapy designation to AYVAKIT for the treatment of advanced SM, including the subtypes of aggressive SM, SM with an associated hematological neoplasm and mast cell leukemia, and for the treatment of moderate to severe indolent SM. The FDA has accepted a supplemental new drug application for avapritinib for the treatment of advanced SM. The European Medicines Agency has validated a Type II variation marketing authorization application for avapritinib for the treatment of advanced SM. Masitinib: AB Sciences Masitinib's anti-mast cell properties appear particularly well-adapted to the treatment of indolent systemic mastocytosis. A reduction of mast cell activity is generated via its inhibitory action on wild-type c-Kit, Lyn and Fyn tyrosine kinases. In recognition of the critical need for new treatments, masitinib received orphan drug designation for mastocytosis from both the European Medicine Agency (EMA) and the U.S. Food and Drug Administration (FDA). AB Science initiated a confirmatory phase 3 study, with design optimized based on findings from the first phase 3 study. The Systemic Mastocytosis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Systemic Mastocytosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Systemic Mastocytosis Treatment. Systemic Mastocytosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Systemic Mastocytosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Systemic Mastocytosis market Explore groundbreaking therapies and clinical trials in the Systemic Mastocytosis Pipeline. Access DelveInsight's detailed report now! @ New Systemic Mastocytosis Drugs Systemic Mastocytosis Companies AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology and others. Systemic Mastocytosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical Molecule Type Systemic Mastocytosis Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Unveil the future of Systemic Mastocytosis Treatment. Learn about new drugs, Systemic Mastocytosis Pipeline developments, and key companies with DelveInsight's expert analysis @ Systemic Mastocytosis Market Drivers and Barriers Scope of the Systemic Mastocytosis Pipeline Report Coverage- Global Systemic Mastocytosis Companies- AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology and others. Systemic Mastocytosis Pipeline Therapies- PA101, Avapritinib, RAD001 (Everolimus), Elenestinib, Masitinib, Avapritinib, Brentuximab vedotin, TL-895 and others. Systemic Mastocytosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Systemic Mastocytosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Systemic Mastocytosis Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Systemic Mastocytosis Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Systemic Mastocytosis: Overview Pipeline Therapeutics Therapeutic Assessment Systemic Mastocytosis – DelveInsight's Analytical Perspective In-depth Commercial Assessment Systemic Mastocytosis Collaboration Deals Late Stage Products (Preregistration) Avapritinib: Blueprint Medicines Drug profiles in the detailed report….. Mid Stage Products (Phase II) PA101: Patara Pharma Drug profiles in the detailed report….. Early stage products (Phase I) DCC-2618: Deciphera Pharmaceuticals Drug profiles in the detailed report….. Inactive Products Systemic Mastocytosis Key Companies Systemic Mastocytosis Key Products Systemic Mastocytosis- Unmet Needs Systemic Mastocytosis- Market Drivers and Barriers Systemic Mastocytosis- Future Perspectives and Conclusion Systemic Mastocytosis Analyst Views Systemic Mastocytosis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
